SEONGNAM, South Korea & CAMBRIDGE, Mass.
Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston June 5-8.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005303/en/
Pavel Printsev, Director of Business Development, will provide a overview of the company’s science and an introduction to its clinical-stage assets:
- BBT-176 – Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, currently in a Phase I/II dose escalation study
- BBT-877 — Autotaxin inhibitor for idiopathic pulmonary fibrosis, currently in a Phase IIa trial
- BBT-207 — Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, which recently received FDA clearance for a first-in-human Phase I/II
Mr. Printsev will also give an overview of Bridge Biotherapeutics’ newly acquired biosensing technology and its plans to commercialize these novel capabilities.
- Date & Time: Tuesday, June 6th, 2023, 3:15 PM (ET)
- Place: Room 104B
- Therapeutic category: Multiple Therapeutics
- To learn more about this session, please visit https://bit.ly/3lEGVDY.
About Bridge Biotherapeutics
Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), BBT-176 and BBT-207, potent targeted cancer therapies for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at bridgebiorx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005303/en/
CONTACT
To arrange an interview with Mr. Printsev, reach out to our media contact:
Jeffrey Krasner
jkrasner@sloweymcmanus.com
+1(617) 840-9806
